Geography and Competitive Outlook United Kingdom (14.2% CAGR), United States (13.8%), Australia (13.1%), and Germany (12.4%) are among the fastest-growing markets, supported by strong adoption of GLP-1 therapies and expanding digital healthcare ecosystems
Appetite suppression is kind of the point
doi: 10.1038/s41598-020-80063-0, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 139
Peptide therapies like the ones we discussed take a complementary approach : rather than suppress appetite dramatically, they optimize the bodys metabolism and hormones to encourage fat loss and muscle retention
Additionally, alcohol can lower inhibitions and lead to overeating or making poor food choices, which can undermine weight management efforts
People who quit taking the popular GLP-1 drugs might actually be jeopardizing their heart health